Peptic Ulcer Drugs Market Size, Share and Report Analysis By Drug Class (Proton Pump Inhibitors (PPIs), Potassium-Competitive Acid Blockers (PCABs), Histamine-2 Receptor Antagonists (H2RAs), Antacids, Antibiotics, Ulcer-Protective Agents), Disease Indication (Gastric Ulcer, Duodenal Ulcer, NSAID-Induced Ulcer, Helicobacter pylori-Associated Ulcer, Stress Ulcer, Refractory Peptic Ulcer), Route of Administration (Oral, Tablets, Capsules, Suspensions, Powders, Injectable), Prescription Type (Prescription Drugs, Over-the-Counter (OTC) Drugs), End User (Hospitals, Specialty Gastroenterology Clinics, Ambulatory Care Centers, Homecare Settings, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2026-2035

Market Overview

Global Peptic Ulcer Drugs Market size is expected to be worth around US$ 7.7 Billion by 2035 from US$ 5.2 Billion in 2025, growing at a CAGR of 4.0% during the forecast period from 2026 to 2035. In 2025, North America led the market, achieving over 36.4% share with a revenue of US$ 1.9 Billion.

Peptic ulcer disease remains a significant gastrointestinal health burden worldwide, sustaining demand for effective acid-suppressive therapies, antibiotic regimens, and mucosal protective agents. The condition is primarily associated with infection by Helicobacter pylori and prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs), both of which continue to influence treatment patterns across healthcare systems.

According to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases, approximately 1% to 6% of the U.S. population experiences peptic ulcers, highlighting the ongoing clinical importance of the disease. Drug development and treatment strategies increasingly focus on improving eradication rates of H. pylori infection and minimizing ulcer recurrence.

Standard treatment approaches generally involve a combination of two or more antibiotics alongside proton pump inhibitors (PPIs), while H2-receptor antagonists and protective agents remain widely used in selected patient groups. Healthcare providers are also emphasizing preventive therapies for patients requiring long-term NSAID use.

Globally, H. pylori infection affects nearly half of the world’s population, making it one of the most prevalent chronic bacterial infections and a major contributor to peptic ulcer disease. Advances in diagnostic testing, improved treatment adherence, and growing awareness regarding gastrointestinal disorders are expected to support continued utilization of peptic ulcer medications.

In addition, aging populations and increasing use of pain-relieving medications are anticipated to sustain demand for effective ulcer management therapies in the coming years.

Key Takeaways

• Market Size : Peptic Ulcer Drugs Market size is expected to be worth around US$ 7.7 Billion by 2035 from US$ 5.2 Billion in 2025.
• Market Share : The Market is growing at a CAGR of 4.0% during the forecast period from 2026 to 2035.
• Drug Class Analysis : The Proton Pump Inhibitors (PPIs) segment dominated the peptic ulcer drugs market in 2025, accounting for 46.8% of total revenue.
• Disease Indication Analysis : Helicobacter pylori-associated ulcers emerged as the leading disease indication segment in 2025, representing 32.6% of the market.
• Route of Administration Analysis : The oral route dominated the peptic ulcer drugs market in 2025, accounting for 89.4% of total revenue.
• Prescription Type Analysis : Prescription drugs led the peptic ulcer drugs market in 2025, capturing 78.3% of total market share.
• End User Analysis : Hospitals dominated the peptic ulcer drugs market in 2025, holding 39.2% of total revenue.
• Distribution Channel Analysis : Retail pharmacies accounted for the largest share of the peptic ulcer drugs market in 2025, representing 48.5% of total revenue.
• Regional Analysis : In 2025, North America led the market, achieving over 36.4% share with a revenue of US$ 1.9 Billion.

Drug Class Analysis

The Proton Pump Inhibitors (PPIs) segment dominated the peptic ulcer drugs market in 2025, accounting for 46.8% of total revenue. PPIs remain the preferred treatment option because they provide strong and long-lasting acid suppression, promote ulcer healing, and are widely recommended in Helicobacter pylori eradication regimens.

Commonly prescribed agents such as omeprazole, pantoprazole, and esomeprazole continue to be used extensively across hospitals and outpatient settings. Antibiotics represented 18.4% of the market owing to their essential role in eliminating H. pylori infections, which remain a major cause of peptic ulcers.

Histamine-2 Receptor Antagonists (H2RAs) accounted for 12.7%, supported by their use in patients intolerant to PPIs and in selected maintenance therapies. Ulcer-protective agents captured 9.5% of the market, particularly for mucosal protection in high-risk patients.

Potassium-Competitive Acid Blockers (PCABs) held 7.2% share and are gaining attention due to rapid acid suppression and improved therapeutic outcomes. Antacids contributed 5.4%, mainly driven by demand for quick symptom relief and easy over-the-counter accessibility.

Disease Indication Analysis

Helicobacter pylori-associated ulcers emerged as the leading disease indication segment in 2025, representing 32.6% of the market. The high prevalence of H. pylori infection worldwide and the continued emphasis on eradication therapy have supported demand for targeted treatment regimens.

Gastric ulcers accounted for 24.8% of market revenue, supported by increasing diagnosis rates through endoscopic procedures and greater awareness regarding gastrointestinal disorders. Duodenal ulcers captured 18.5%, driven by persistent associations with H. pylori infection and excess acid secretion.

NSAID-induced ulcers represented 11.7% of the market as prolonged use of pain-relieving medications remains common among aging populations and patients with chronic diseases. Stress ulcers contributed 7.1%, particularly in critically ill and hospitalized patients requiring preventive therapies.

Refractory peptic ulcers held 5.3% share, reflecting cases that are resistant to conventional treatments or linked with recurrent infections. Improved diagnostic capabilities and growing use of combination therapies continue to support growth across all disease categories.

Route of Administration Analysis

The oral route dominated the peptic ulcer drugs market in 2025, accounting for 89.4% of total revenue. Oral formulations remain highly preferred due to convenience, ease of administration, cost-effectiveness, and strong patient compliance. Tablets represent the largest category within oral formulations, as most PPIs, antibiotics, H2RAs, and ulcer-protective agents are available in tablet form.

Capsules also maintain a notable presence because of their ability to enhance drug stability and improve patient acceptance. Suspensions are commonly prescribed for pediatric and elderly patients experiencing swallowing difficulties. Powder formulations continue to find applications in specialized treatment settings.

Injectable therapies occupy a relatively small share but remain important in acute care environments, particularly for patients with severe gastrointestinal bleeding, stress ulcers, or those unable to take oral medications. The increasing availability of advanced oral acid-suppressing drugs, including PCABs, further strengthens the dominance of oral administration within the market.

Prescription Type Analysis

Prescription drugs led the peptic ulcer drugs market in 2025, capturing 78.3% of total market share. This dominance is primarily attributed to the clinical complexity associated with peptic ulcer disease and the requirement for physician-supervised treatment protocols.

Prescription medicines are essential for H. pylori eradication therapies, which typically involve combinations of antibiotics and proton pump inhibitors. They are also widely used in the management of gastric ulcers, duodenal ulcers, and NSAID-induced ulcers requiring long-term therapy.

Over-the-counter (OTC) drugs accounted for the remaining share of the market and are largely represented by antacids and selected low-dose acid suppressants. OTC products continue to gain demand among consumers seeking rapid relief from mild symptoms such as indigestion and heartburn.

However, increasing awareness regarding appropriate diagnosis and the importance of targeted therapies continues to favor prescription-based treatment approaches, particularly in developed healthcare systems.

End User Analysis

Hospitals dominated the peptic ulcer drugs market in 2025, holding 39.2% of total revenue. Hospitals remain the primary treatment centers for patients suffering from severe ulcer complications, gastrointestinal bleeding, perforations, and recurrent ulcer conditions.

Access to endoscopic procedures, specialist consultations, and advanced treatment options supports their leading position. Specialty gastroenterology clinics represent an important segment as demand for dedicated digestive healthcare services continues to increase globally.

Ambulatory care centers are gaining traction because they provide cost-effective treatment, diagnostic services, and follow-up care for uncomplicated ulcer cases. Homecare settings are also expanding, supported by the growing availability of oral medications and improved patient awareness regarding long-term ulcer management.

Other end users, including community healthcare facilities, continue to contribute to market growth. Rising incidence of gastrointestinal disorders, increasing healthcare access, and the shift toward patient-centered treatment models are expected to sustain demand across all end-user categories.

Distribution Channel Analysis

Retail pharmacies accounted for the largest share of the peptic ulcer drugs market in 2025, representing 48.5% of total revenue. Their dominance is supported by widespread accessibility, strong consumer trust, and the availability of both prescription and over-the-counter gastrointestinal medications.

Patients frequently rely on retail pharmacy networks for refilling long-term PPI prescriptions, antibiotic therapies, and ulcer-protective agents. Hospital pharmacies continue to maintain a substantial market presence, particularly in managing hospitalized patients requiring specialized ulcer treatments, intravenous formulations, or post-procedure medications.

Online pharmacies are witnessing steady growth due to increasing digital healthcare adoption, home delivery services, and greater patient convenience. The expansion of e-commerce platforms and telemedicine services is further strengthening this segment.

Growing healthcare awareness, improved medicine accessibility, and evolving consumer purchasing behavior are expected to support continued expansion across all distribution channels.

Market Segmentations

Drug Class

• Proton Pump Inhibitors (PPIs)
• Potassium-Competitive Acid Blockers (PCABs)
• Histamine-2 Receptor Antagonists (H2RAs)
• Antacids
• Antibiotics
• Ulcer-Protective Agents

Disease Indication

• Gastric Ulcer
• Duodenal Ulcer
• NSAID-Induced Ulcer
• Helicobacter pylori-Associated Ulcer
• Stress Ulcer
• Refractory Peptic Ulcer

Route of Administration

• Oral
• Tablets
• Capsules
• Suspensions
• Powders
• Injectable

Prescription Type

• Prescription Drugs
• Over-the-Counter (OTC) Drugs

End User

• Hospitals
• Specialty Gastroenterology Clinics
• Ambulatory Care Centers
• Homecare Settings
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Drivers

PCAB Uptake Expands Premium Acid Suppression Mix

A key growth driver in acid related disorders is the gradual adoption of potassium competitive acid blockers (PCABs), particularly vonoprazan based regimens, which shift treatment from low cost proton pump inhibitors (PPIs) toward higher value branded therapies.

Regulatory labeling, including VOQUEZNA dual and triple packs, supports use in H. pylori eradication, while 2024 ACG guidance recognizes vonoprazan amoxicillin dual therapy as a first line alternative, expanding clinical acceptance beyond reflux disease.

This shift is driven less by higher disease incidence and more by therapy mix upgrading. Compared with traditional bismuth quadruple therapy (which can involve up to four drugs and frequent daily dosing), PCAB based regimens simplify treatment complexity, improving adherence and patient convenience. This creates room for premium co packaging strategies and branded combination products that can command higher pricing.

Market adoption is strongest in the U.S. and Japan, where formulary systems and reimbursement pathways more readily support differentiated GI therapies. In contrast, uptake in lower income markets remains slower due to cost sensitivity and continued reliance on generic PPIs.

Importantly, PCABs do not replace PPIs entirely but rather carve out a higher value subsegment within acid suppression therapy. The result is structural mix enrichment, improved persistence in eradication therapy, and lifecycle extension opportunities for branded packs.

Overall, this transition is expected to contribute approximately 0.9 % points of incremental CAGR, driven primarily by pricing uplift, improved adherence, and expanded use in H. pylori treatment pathways.

Challenges

NSAID Exposure and Comorbidity Complexity

NSAIDs remain the second leading cause of peptic ulcer disease after H. pylori, and their widespread use in aging populations creates a persistent but clinically complex demand base for gastroprotection. In many high income countries, 20–30 % of adults over 60 use NSAIDs chronically for musculoskeletal pain, often alongside other comorbidities such as cardiovascular disease, renal impairment, and diabetes.

This creates a non linear risk environment for every 1,000 chronic NSAID users, approximately 25–50 develop clinically significant ulcers annually, and 5–10 require hospitalization. While gastroprotective therapy with PPIs or similar agents is guideline recommended, real world adherence remains below 70 %, largely due to pill burden, cost sharing, and competing medication priorities in polypharmacy patients.

Clinical management is further complicated by overlapping risk factors such as age, anticoagulant use, prior GI bleeding, and renal dysfunction, which require dynamic risk stratification and frequent treatment adjustments. Despite guidelines, roughly 10–15 % of high risk patients do not receive optimal prophylaxis, limiting incremental uptake of preventive therapies.

At the system level, efforts to reduce unnecessary NSAID prescribing by 5–10 % and shift a portion of patients toward alternative analgesics further dampen growth in prophylactic ulcer treatment volumes.

Overall, this complexity creates a cautious, risk adjusted prescribing environment that slows net market expansion, contributing an estimated 0.8 % point drag on CAGR, even as acute ulcer management remains clinically important.

Restraints

Tightening Payer and HTA Controls in Peptic Ulcer and Acid Suppression Therapies

Tightening payer policies and health technology assessment (HTA) requirements are increasingly constraining growth in the peptic ulcer and acid suppression market, reducing forecast CAGR by an estimated 0.9 % points through pricing and utilization restrictions.

Across major EU markets and the UK, HTA bodies now require stronger real world effectiveness evidence before approving reimbursement for new acid suppressive or ulcer adjunct therapies. This has reinforced step therapy pathways, where patients typically must try low cost generics such as PPIs or H2 blockers before accessing higher priced branded options, keeping average treatment costs tightly controlled.

In North America, integrated delivery networks and pharmacy benefit managers routinely narrow formularies through rebate driven contracting and periodic tender cycles. These mechanisms often lead to 5–10 % price resets every 2 to 3 years, while also steering prescribing toward lowest net cost therapies, limiting uptake of premium agents even when clinically differentiated.

Operationally, manufacturers face rising administrative burden, including prior authorizations, reimbursement appeals, and the need for extensive real world evidence generation and health economic modeling.

These requirements delay market access and slow adoption of newer therapies, particularly in marginal or extended use indications. Strategically, this environment favors incremental innovation such as improved healing rates or reduced rebleeding in high risk NSAID patients over premium pricing models.

While clinically meaningful advances can still succeed, HTA driven constraints increasingly cap pricing power and reduce overall revenue upside in ulcer related therapies.

Opportunity

Value Based PUD Care Pathways with Payers

A key opportunity in peptic ulcer disease (PUD) management is the shift toward value based reimbursement models, where payments are tied to clinical outcomes rather than prescription volume. Instead of reimbursing only drug dispensing, payers increasingly focus on measurable reductions in ulcer related complications such as hospitalizations, emergency endoscopies, transfusions, and re-bleeding events.

This model is particularly relevant because a disproportionate share of PUD economic burden comes from acute complications rather than routine treatment. Even a 10 to 15 % reduction in ulcer related hospital admissions in high income systems where annual cases number in the tens of thousands can translate into substantial cost savings at the health system level.

Under value based arrangements, manufacturers and care providers could earn outcomes based bonuses, bundled payments, or shared savings agreements in exchange for demonstrating improved adherence, optimized therapy selection, and reduced complication rates.

Target agreements may aim for 20 to 30 % reductions in PUD related emergency interventions over 3 to 5 years. While most current PUD therapies remain commoditized and low margin, value based contracts shift monetization toward performance and coordination of care rather than unit volume alone.

However, adoption is still limited due to data integration challenges and payer conservatism, likely confined initially to large US and EU insurers covering 10 to 20 % of high risk populations by 2030. Despite early stage penetration, this model could support a 5 to 10 % revenue uplift within participating cohorts and contribute approximately 1.5 % points of CAGR upside, driven by higher realized pricing and more protocol driven, sustained utilization.

Regional Analysis

In 2025, North America dominated the peptic ulcer drugs market, accounting for over 36.4% of global revenue and reaching US$ 1.9 billion. The region’s leadership is supported by a well-established healthcare infrastructure, widespread availability of prescription and over-the-counter gastrointestinal medications, and strong awareness regarding ulcer diagnosis and treatment.

The United States remains the major contributor due to high healthcare spending, extensive insurance coverage, and broad access to advanced diagnostic procedures such as endoscopy and Helicobacter pylori testing. Studies indicate that peptic ulcer disease continues to affect a considerable patient population in the region, sustaining demand for proton pump inhibitors, antibiotics, and emerging acid-suppressing therapies.

Europe represents another important regional market, driven by favorable reimbursement systems, increasing adoption of guideline-based treatment approaches, and growing emphasis on H. pylori eradication strategies.

Meanwhile, Asia-Pacific is expected to register the fastest growth during the forecast period owing to its large patient base, rising healthcare investments, improving access to gastrointestinal medicines, and relatively higher prevalence of H. pylori infection in several countries.

Expanding healthcare infrastructure, growing awareness of digestive disorders, and increasing use of innovative therapies such as potassium-competitive acid blockers are expected to support market expansion across emerging economies in the coming years.

Key Regions and Countries

North America

• The US
• Canada

Europe

• Germany
• France
• The U.K.
• Italy
• Spain
• Russia & CIS
• Rest of Europe

Asia Pacific

• China
• India
• Japan
• South Korea
• ASEAN
• Australia & New Zealand
• Rest of Asia Pacific

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa

Latin America

• Brazil
• Mexico
• Rest of Latin America

Key Player Analysis

The peptic ulcer drugs market is supported by the strong global presence, established gastrointestinal portfolios, and extensive distribution capabilities of leading pharmaceutical companies. Takeda Pharmaceutical remains one of the most influential participants due to its focus on innovative acid-suppressing therapies, particularly vonoprazan, which has gained wider commercialization through licensing partnerships in major markets including India.

AstraZeneca plc continues to maintain a significant position through its long-standing proton pump inhibitor portfolio, while Pfizer Inc., Sanofi S.A., and Abbott Laboratories benefit from diversified pharmaceutical businesses and broad access to hospital and retail healthcare channels worldwide.

Novartis AG and Boehringer Ingelheim leverage their research capabilities and global commercial networks to strengthen their presence across gastrointestinal therapeutics. Meanwhile, Daiichi Sankyo continues to contribute through its expertise in specialty medicines and regional pharmaceutical operations.

Growing emphasis on advanced acid suppression therapies, improved Helicobacter pylori eradication strategies, and expansion into emerging markets is encouraging companies to invest in product innovation, lifecycle management, and strategic collaborations to sustain competitiveness within the peptic ulcer drugs sector.

Top Key Players

• Pfizer Inc.
• Novartis AG
• Takeda Pharmaceutical
• AstraZeneca plc
• Sanofi S.A.
• Abbott Laboratories
• Daiichi Sankyo
• Boehringer Ingelheim
• Cadila Healthcare (Zydus)
• Ranbaxy Laboratories
• Daewoong Pharmaceutical
• Helicure AB
• MedicoPharm Ltd.
• Gastrotech Pharmaceuticals
• BioCure Pharmaceuticals
• Other Key Players

Recent Developments

• April 2025 – Sun Pharmaceutical Industries commercially launched FEXUCLUE® in India under a licensing arrangement with Daewoong Pharmaceutical, strengthening its gastroenterology portfolio with a next-generation acid suppression therapy aimed at acid-related disorders, including peptic ulcer management.
• December 2025 – Daewoong Pharmaceutical expanded the clinical positioning of Pexuclu® in South Korea through approval for prevention of NSAID-induced peptic ulcers, representing one of the few notable ulcer-focused product developments reported during the 2025–2026 period.

Report Scope